atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101
Posted:
atai Life Sciences, a clinical stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced additional clinical data from the Kures Therapeutics Phase 1 trial of KUR-101 in healthy volunteers. This two-part trial was designed to assess the safety, tolerability, pharmacokinetics, and analgesic activity of KUR-101. Read more here.
A new study led by researchers from VIB and KU Leuven shows that Parkinson's disease can be divided into distinct subtypes, helping explain why a single treatment does not work for all patients. Using a machine-learning-driven analysis, the team identified…
4basebio PLC, a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces a significant expansion into a new innovation hub and manufacturing facility in Cambridge, UK, supporting growing demand for research and high-quality grade manufacturing of synthetic…
Attendees
Sponsors and Exhibitors
Contact us